Treatment of invasive aspergillosis: Polyenes, echinocandins, or azoles?

References

• Lin SJ, Schranz J, Teutsch SM. Aspergillosis case – Fatality rate: Systematic review of the literature. Clin Infect Dis 2001; 32: 358–366
   PubMed Web of Science ®Google Scholar
• Patterson TF, Kirkpatrick WR, White M, et al. Invasive aspergillosis. Disease spectrum, treatment practices, and outcomes. I3 Aspergillus Study Group. Medicine (Baltimore) 2000; 79: 250–260
   PubMed Web of Science ®Google Scholar
• Ostrosky-Zeichner L, Marr KA, Rex JH, et al. Amphotericin B: time for a new ‘gold standard’. Clin Infect Dis 2003; 37: 415–425
   PubMed Web of Science ®Google Scholar
• Patterson TF, Boucher HW, Herbrecht R, et al. Strategy of following voriconazole versus amphotericin B therapy with other licensed antifungal therapy for primary treatment of invasive aspergillosis: impact of other therapies on outcome. Clin Infect Dis 2005; 41: 1448–1452
   PubMed Web of Science ®Google Scholar
• Patterson TF. Advances and challenges in the management of invasive mycoses. Lancet 2005; 366: 1013–1025
   PubMed Web of Science ®Google Scholar
• Wingard JR, Kubilis P, Lee L, et al. Clinical significance of nephrotoxicity in patients treated with amphotericin B for suspected or proven aspergillosis. Clin Infect Dis 1999; 29: 1402–1407
   PubMed Web of Science ®Google Scholar
• Bates DW, Su L, Yu DT, et al. Mortality and costs of acute renal failure associated with amphotericin B therapy. Clin Infect Dis 2001; 32: 686–693
   PubMed Web of Science ®Google Scholar
• Steinbach WJ, Benjamin DK, Jr, Kontoyiannis DP, et al. Infections due to Aspergillus terreus: a multicenter retrospective analysis of 83 cases. Clin Infect Dis 2004; 39: 192–198
   PubMed Web of Science ®Google Scholar
• Sutton DA, Fothergill AW, Rinaldi MG. Aspergillus in vitro antifungal susceptibility data: New millennium trends (abstract 16). In: Abstracts of Advances Against Aspergillosis, San Francisco, CA, 9–11 September 2004. 2004 p 60.
   Google Scholar
• Walsh TJ, Finberg RW, Arndt C, et al. Liposomal amphotericin B for empirical therapy in patients with persistent fever and neutropenia. N Engl J Med 1999; 340: 764–771
   PubMed Web of Science ®Google Scholar
• Walsh TJ, Goodman JL, Pappas P, et al. Safety, tolerance, and pharmacokinetics of high-dose liposomal amphotericin B (AmBisome) in patients infected with Aspergillus species and other filamentous fungi: Maximum tolerated dose study. Antimicrob Agents Chemother 2001; 45: 3487–3496
   PubMed Web of Science ®Google Scholar
• Walsh TJ, Teppler H, Donowitz GR, et al. Caspofungin versus liposomal amphotericin B for empirical antifungal therapy in patients with persistent fever and neutropenia. N Engl J Med 2004; 351: 1391–1402
   PubMed Web of Science ®Google Scholar
• Bowden R, Chandrasekar P, White MH, et al. A double-blind, randomized, controlled trial of amphotericin B colloidal dispersion versus amphotericin B for treatment of invasive aspergillosis in immunocompromised patients. Clin Infect Dis 2002; 35: 359–366
   PubMed Web of Science ®Google Scholar
• Ellis M, Spence D, de Pauw B, et al. An EORTC international multicenter randomized trial (EORTC number 19923) comparing two dosages of liposomal amphotericin B for treatment of invasive aspergillosis. Clin Infect Dis 1998; 27: 1406–1412
   PubMed Web of Science ®Google Scholar
• Linden PK, Coley K, Fontes P, et al. Invasive aspergillosis in liver transplant recipients: outcome comparison of therapy with amphotericin B lipid complex and a historical cohort treated with conventional amphotericin B. Clin Infect Dis 2003; 37: 17–25
   PubMed Web of Science ®Google Scholar
• Barrett JP, Vardulaki KA, Conlon C, et al. A systematic review of the antifungal effectiveness and tolerability of amphotericin B formulations. Clin Ther 2003; 25: 1295–1320
   PubMed Web of Science ®Google Scholar
• Cornely OA, Maertens J, Bresnik M, et al. Liposomal amphotericin B (L-AMB) as initial therapy for invasive filamentous fungal infections (IFFI): A randomized, prospective trial of a high loading regimen vs. standard dosing (AmBiLoad Trial). Blood (ASH Annual Meeting Abstracts) 2005; 106: 3222
   Web of Science ®Google Scholar
• Imhof A, Walter RB, Schaffner A. Continuous infusion of escalated doses of amphotericin B deoxycholate: an open-label observational study. Clin Infect Dis 2003; 36: 943–951
   PubMed Web of Science ®Google Scholar
• Andes D, Stamsted T, Conklin R. Pharmacodynamics of amphotericin B in a neutropenic-mouse disseminated-candidiasis model. Antimicrob Agents Chemother 2001; 45: 922–926
   PubMed Web of Science ®Google Scholar
• Denning DW. Echinocandin antifungal drugs. Lancet 2003; 362: 1142–1151
   PubMed Web of Science ®Google Scholar
• Bowman JC, Hicks PS, Kurtz MB, et al. The antifungal echinocandin caspofungin acetate kills growing cells of Aspergillus fumigatus in vitro. Antimicrob Agents Chemother 2002; 46: 3001–3012
   PubMed Web of Science ®Google Scholar
• Maertens J, Raad I, Petrikkos G, et al. Efficacy and safety of caspofungin for treatment of invasive aspergillosis in patients refractory to or intolerant of conventional antifungal therapy. Clin Infect Dis 2004; 39: 1563–1571
   PubMed Web of Science ®Google Scholar
• Perea S, Gonzalez G, Fothergill AW, et al. In vitro interaction of caspofungin acetate with voriconazole against clinical isolates of Aspergillus spp. Antimicrob Agents Chemother 2002; 46: 3039–3041
   PubMed Web of Science ®Google Scholar
• Petraitis V, Petraitiene R, Sarafandi AA, et al. Combination therapy in treatment of experimental pulmonary aspergillosis: synergistic interaction between an antifungal triazole and an echinocandin. J Infect Dis 2003; 187: 1834–1843
   PubMed Web of Science ®Google Scholar
• Kirkpatrick WR, Perea S, Coco BJ, et al. Efficacy of caspofungin alone and in combination with voriconazole in a Guinea pig model of invasive aspergillosis. Antimicrob Agents Chemother 2002; 46: 2564–2568
   PubMed Web of Science ®Google Scholar
• Aliff TB, Maslak PG, Jurcic JG, et al. Refractory Aspergillus pneumonia in patients with acute leukemia: successful therapy with combination caspofungin and liposomal amphotericin. Cancer 2003; 97: 1025–1032
   PubMed Web of Science ®Google Scholar
• Kontoyiannis DP, Hachem R, Lewis RE, et al. Efficacy and toxicity of caspofungin in combination with liposomal amphotericin B as primary or salvage treatment of invasive aspergillosis in patients with hematologic malignancies. Cancer 2003; 98: 292–299
   PubMed Web of Science ®Google Scholar
• Steinbach WJ, Stevens DA, Denning DW. Combination and sequential antifungal therapy for invasive aspergillosis: review of published in vitro and in vivo interactions and 6281 clinical cases from to 2001. Clin Infect Dis 2003; 37(Suppl 3)S188–S224
   Google Scholar
• Marr KA, Boeckh M, Carter RA, et al. Combination antifungal therapy for invasive aspergillosis. Clin Infect Dis 2004; 39: 797–802
   PubMed Web of Science ®Google Scholar
• Marr KA, Crippa F, Leisenring W, et al. Itraconazole versus fluconazole for prevention of fungal infections in patients receiving allogeneic stem cell transplants. Blood 2004; 103: 1527–1533
   PubMed Web of Science ®Google Scholar
• Pfaller MA, Messer SA, Hollis RJ, et al. Antifungal activities of posaconazole, ravuconazole, and voriconazole compared to those of itraconazole and amphotericin B against 239 clinical isolates of Aspergillus spp. and other filamentous fungi: Report from SENTRY Antimicrobial Surveillance Program, 2000. Antimicrob Agents Chemother 2002; 46: 1032–1037
   PubMed Web of Science ®Google Scholar
• Herbrecht R, Denning DW, Patterson TF, et al. Voriconazole versus amphotericin B for primary therapy of invasive aspergillosis. N Engl J Med 2002; 347(6)408–15
   PubMed Web of Science ®Google Scholar
• Steinbach WJ, Stevens DA. Review of newer antifungal and immunomodulatory strategies for invasive aspergillosis. Clin Infect Dis 2003; 37(Suppl 3)S157–S187
   PubMedGoogle Scholar
• Denning DW, Ribaud P, Milpied N, et al. Efficacy and safety of voriconazole in the treatment of acute invasive aspergillosis. Clin Infect Dis 2002; 34: 563–571
   PubMed Web of Science ®Google Scholar
• Schwartz S, Ruhnke M, Ribaud P, et al. Improved outcome in central nervous system aspergillosis, using voriconazole treatment. Blood 2005; 106: 2641–2645
   PubMed Web of Science ®Google Scholar
• Kauffman CA. Zygomycosis: reemergence of an old pathogen. Clin Infect Dis 2004; 39: 588–590
   PubMed Web of Science ®Google Scholar
• Smith J, Safdar N, Knasinski V, et al. Voriconazole therapeutic drug monitoring. Antimicrob Agents Chemother 2006; 50: 1570–1572
   PubMed Web of Science ®Google Scholar
• Raad I, Chapman S, Bradsher R, , et al Posaconazole (POS) salvage therapy for invasvie fungal infections (IFI) (abstract M-699). In: Abstracts of the 44th Interscience Conference on Antimicrobial Agents and Chemotherapy, Washington, DC, 30 October–2 November 2004. WashingtonDC: American Society for Microbiology, 2004. p 412.
   Google Scholar
• Ullmann AJ, Lipton JH, Vesole DH, , et al Posaconazole (POS) vs fluconazole (FLU) for prophylaxis of invasive fungal infections (IFIs) in allogeneic hematopoietic stem cell transplant (HSCT) recipients with graft-versus-host-disease (GVHD): Results of a multicenter trial (abstract M-716). In: Abstracts of the 45th Interscience Conference on Antimicrobial Agents and Chemotherapy, 16–19 December 2005, WashingtonDC: American Society for Microbiology, 2005: 39.
   Google Scholar
• Cornely OA, Maertens J, Winston DJ, , et al Posaconazole (POS) vs. standard azoles as antifungal prophylaxis in neutropenic patients with acute myelogenous leukemia (AML) or myelodysplastic syndrome (MDS): Impact on mortality (abstract M-722b). In: Abstracts of the 45th Interscience Conference on Antimicrobial Agents and Chemotherapy, 16–19 December, 2005. WashingtonDC: American Society for Microbiology, 2005: 207.
   Google Scholar
• Maertens J, Theunissen K, Verhoef G, et al. Galactomannan and computed tomography-based preemptive antifungal therapy in neutropenic patients at high risk for invasive fungal infection: a prospective feasibility study. Clin Infect Dis 2005; 41: 1242–1250
   PubMed Web of Science ®Google Scholar
• Donnelly JP. Polymerase chain reaction for diagnosing invasive aspergillosis: Getting closer but still ways to go. Clin Infect Dis 2006; 42: 487–489
   PubMed Web of Science ®Google Scholar
• Marr KA, Balajee SA, McLaughlin L, et al. Detection of galactomannan antigenemia by enzyme immunoassay for the diagnosis of invasive aspergillosis: variables that affect performance. J Infect Dis 2004; 190: 641–649
   PubMed Web of Science ®Google Scholar
• Odabasi Z, Mattiuzzi G, Estey E, et al. Beta-D-glucan as a diagnostic adjunct for invasive fungal infections: validation, cutoff development, and performance in patients with acute myelogenous leukemia and myelodysplastic syndrome. Clin Infect Dis 2004; 39: 199–205
   PubMed Web of Science ®Google Scholar
• White PL, Linton CJ, Perry MD, et al. The evolution and evaluation of a whole blood polymerase chain reaction assay for the detection of invasive aspergillosis in hematology patients in a routine clinical setting. Clin Infect Dis 2006; 42: 479–486
   PubMed Web of Science ®Google Scholar
• Wingard JR, White MH, Anaissie E, et al. A randomized, double-blind comparative trial evaluating the safety of liposomal amphotericin B versus amphotericin B lipid complex in the empirical treatment of febrile neutropenia. Clin Infect Dis 2000; 31: 1155–1163
   PubMed Web of Science ®Google Scholar
• Leenders ACAP, Daenen S, Jansen RLH, et al. Liposomal amphotericin B compared with amphotericin B deoxycholate in the treatment of documented and suspected neutropenia-associated invasive fungal infections. Brit J Haematol 1998; 103: 205–212
   PubMed Web of Science ®Google Scholar
• Caillot D, Bassaris H, McGeer A, et al. Intravenous itraconazole followed by oral itraconazole in the treatment of invasive pulmonary aspergillosis in patients with hematologic malignancies, chronic granulomatous disease, or AIDS. Clin Infect Dis 2001; 33(8)E83–E90
   PubMed Web of Science ®Google Scholar